0.6901
2.11%
-0.0148
アフターアワーズ:
.71
0.0199
+2.89%
前日終値:
$0.7049
開ける:
$0.6829
24時間の取引高:
24,123
Relative Volume:
0.69
時価総額:
$28.07M
収益:
-
当期純損益:
$-24.77M
株価収益率:
-0.8962
EPS:
-0.77
ネットキャッシュフロー:
$-17.36M
1週間 パフォーマンス:
-7.99%
1か月 パフォーマンス:
-0.14%
6か月 パフォーマンス:
-30.30%
1年 パフォーマンス:
-33.65%
Mink Therapeutics Inc Stock (INKT) Company Profile
INKT を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
INKT | 0.6901 | 28.07M | 0 | -24.77M | -17.36M | -0.77 |
VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 596.74 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 108.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Mink Therapeutics Inc (INKT) 最新ニュース
MiNK Therapeutics (NASDAQ:INKT) Given New $4.00 Price Target at Robert W. Baird - Defense World
Bright Mountain Media, Inc. Enters into Executive Employment Agreement with CEO Matthew DrinkwaterOn November 8, 2024, Bright Mountain Media, Inc. (OTCMKTS:BMTM) announced in an 8-K filing that they had entered into an Executive Employment Agr - Defense World
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2024 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics stock target cut, rating held amid pipeline updates By Investing.com - Investing.com UK
MiNK Therapeutics Inc (INKT) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
MiNK Therapeutics Reports Q3 Growth and Strategic Advances - TipRanks
Earnings call: MiNK Therapeutics succeeded in reducing costs by 60% - Investing.com
MiNK Therapeutics Inc (INKT) Quarterly 10-Q Report - Quartzy
Agenus (AGEN) Stock Dips Amid Financial Performance and Industry Trends - GuruFocus.com
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update - GlobeNewswire
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report - GlobeNewswire
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
MiNK Therapeutics Sets Q3 2024 Earnings Call: iNKT Cell Therapy Updates Ahead | INKT Stock News - StockTitan
Hedge funds pile into banks, dump green energy post US election, Goldman Sachs says - Yahoo Canada Finance
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024 - GlobeNewswire
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid - The Bakersfield Californian
AGENAgenus Inc. Latest Stock News & Market Updates - StockTitan
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update - Business Wire
MiNK Therapeutics Appoints Dr. Robert Kadlec to Board - TipRanks
Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024 - The Manila Times
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors - GlobeNewswire
Small Cell Lung Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
BBerg Commodity Index (AHH20) Quote - The Globe and Mail
TSX Industrials Capped Index (TTIN) QuotePress Release - The Globe and Mail
Altria Group (MO-N) QuotePress Release - The Globe and Mail
TSX 60 Equal Weight Index (TXEW) QuotePress Release - The Globe and Mail
TSX Energy Capped Index (TTEN) QuotePress Release - The Globe and Mail
Refractory Multiple Myeloma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Realty Income Corp (O-N) QuotePress Release - The Globe and Mail
TSX Global Base Metals Index (TXBM) QuotePress Release - The Globe and Mail
Nasdaq Biotechnology Index (NBI) QuotePress Release - The Globe and Mail
Alphabet Cl C (GOOG-Q) QuotePress Release - The Globe and Mail
Refractory Multiple Myeloma Pipeline Therapeutics, - openPR
Vertiv Holdings Llc. (VRT-N) QuotePress Release - The Globe and Mail
S&P 500 Information Technology [Sector] (SRIT) QuotePress Release - The Globe and Mail
Meta Platforms Inc (META-Q) QuotePress Release - The Globe and Mail
CAR-T Cell Therapy Competitive Landscape 2024 (Updated) - openPR
MiNK Therapeutics announces executive transition By Investing.com - Investing.com Australia
MiNK Therapeutics announces executive transition - Investing.com India
Renaissance Technologies LLC Makes New Investment in Team, Inc. (NYSE:TISI) - Defense World
Rx Rundown: AstraZeneca, Danco Laboratories, GSK and more - MM+M Online
Poseida Therapeutics’ Allogeneic CAR-T P-BCMA-ALLO1 Demonstrates 91% ORR in Enhanced Lymphodepletion Arm of R/R MM Study - CGTLive™
MiNK Therapeutics Inc (INKT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Around the Helix: Cell and Gene Therapy Company Updates – October 9, 2024 - CGTLive™
MiNK Therapeutics stock gets boost from new RNA collaboration with Autonomous - Investing.com Canada
Mink Therapeutics and Autonomous Therapeutics target metastatic tumors through new collaboration - BioWorld Online
Investor’s Toolkit: Key Ratios for Assessing MiNK Therapeutics Inc (INKT)’s Performance - The Dwinnex
MiNK Therapeutics, Autonomous Therapeutics enter research collaboration - TipRanks
Mink Therapeutics Inc (INKT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):